Hormonal physiology describes the set of processes that lead from the biosynthesis of a chemical signal to its biological action on target cells, including secretion, transport through extracellular compartments, access to receptors, peripheral conversion into more or less active metabolites and, finally, clearance with inactivation and elimination. In an integrated sense, a hormone is never merely a circulating molecule, but the measurable result of a chain of events that includes availability of precursors and cofactors, biosynthetic capacity of the endocrine tissue, release dynamics (pulsatile, ultradian, circadian), binding to carrier proteins, tissue distribution, transmembrane transport when required, intra- and extracellular metabolism and feedback regulations that remodel the entire functional axis in real time.
The complexity of modern endocrinology derives from the fact that the same plasma concentration may correspond to different biological states depending on the free fraction versus the bound fraction, the presence of variable transport proteins, receptor sensitivity and local conversion of the hormone within the target compartment. The final effect is therefore the result of an endogenous “physiological pharmacokinetics”, in which production, distribution and removal jointly determine receptor exposure, and in which endocrine information is encoded not only quantitatively, but also temporally, that is, in the shape and frequency of the secretory signal.
This page examines the general principles governing hormone synthesis, secretion and transport, using a cross-sectional framework applicable to the main molecular classes, from peptides to amino acid derivatives, steroids and lipophilic hormones that act through nuclear receptors. The aim is to make explicit the logical sequence that links the chemistry of the hormone to the cellular mechanisms of production and release, through to bioavailability and tissue distribution, highlighting the critical points that explain many clinical differences between endocrine axes and many apparent discrepancies between laboratory results and phenotype.
The chemical nature of a hormone determines almost every aspect of its physiology: site and mode of synthesis, storage pattern, release mechanism, blood transport, ability to cross membranes and receptor type. From a functional perspective, at least four broad groups are useful to distinguish: peptide and protein hormones, amino acid-derived hormones, steroid hormones and non-steroidal lipophilic hormones (such as vitamin D derivatives and retinoids), alongside hormone-like mediators (eicosanoids, gasotransmitters) often acting predominantly in a paracrine or autocrine manner. This classification is not merely descriptive, but predicts the entire “logistics” of endocrine information.
Peptide and protein hormones, including insulin, glucagon, adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), luteinizing hormone (LH)/follicle-stimulating hormone (FSH), parathyroid hormone (PTH) and many cytokines with endocrine roles, are gene-encoded and produced through ribosomal translation as preprohormones. The presence of a signal peptide directs the nascent chain into the endoplasmic reticulum, where folding begins and disulfide bonds are established when required. Conversion into a prohormone and then into an active hormone depends on specific proteases (prohormone convertases), carboxypeptidases and post-translational modifications such as amidation or glycosylation, which may be essential for stability, intracellular trafficking or receptor affinity. The Golgi apparatus and the secretory granule compartment function as an assembly line and storage system: the hormone is accumulated in dense-core vesicles and released in a regulated manner, enabling rapid responses to neural or humoral stimuli. This mechanism explains why many peptide hormones have short half-lives and pulsatile plasma profiles, and why dynamic tests assessing “secretory reserve” are often informative.
Amino acid-derived hormones include two subgroups with profoundly different physiology. Catecholamines (dopamine, noradrenaline, adrenaline) derive from tyrosine and are synthesized in the cytosol and in chromaffin vesicles through sequential enzymes; they are stored in granules and released through calcium-dependent exocytosis, similarly to peptides, but with even faster kinetics and predominantly membrane receptor-mediated action. At the opposite end, thyroid hormones (thyroxine, T4, and triiodothyronine, T3), although also derived from tyrosine, are synthesized in a specialized extracellular compartment, the follicular colloid, through iodination and coupling on thyroglobulin. In this case, the gland does not store the finished hormone in cytosolic granules, but retains a large protein-bound reserve in the follicular lumen; secretion depends on endocytosis of iodinated thyroglobulin and lysosomal proteolysis, and systemic availability is modulated by plasma transport and peripheral conversion through deiodinases, with a physiology that favors stability and regulation over hours to days.
Steroid hormones (cortisol, aldosterone, androgens, estrogens, progesterone) derive from cholesterol and share a cardinal principle: they are not stored in large amounts as finished products, but are synthesized “on demand” in response to trophic stimuli, because their lipophilic structure allows diffusion across membranes once they are produced. The rate-limiting step is often the availability of cholesterol in the inner mitochondrial membrane, where steroidogenesis begins with side-chain cleavage. Cholesterol mobilization from lipid droplets, mitochondrial import and acute regulation by dedicated proteins, particularly steroidogenic acute regulatory protein (StAR), constitute a crucial control point integrating second-messenger signals (cyclic adenosine monophosphate/protein kinase A, cAMP/PKA, in many steroidogenic cells) and substrate availability. Subsequent steps depend on mitochondrial and microsomal cytochrome P450 enzymes and dehydrogenases, with a tissue-specific “enzymatic map” that explains the diversity of output among the adrenal cortex, gonads and placenta. Since the hormone is produced and released almost simultaneously, steroid secretion sensitively reflects trophic stimulus dynamics and the enzymatic capacity of the tissue.
Non-steroidal lipophilic hormones include the active form of vitamin D and retinoids, which share nuclear receptors and transcriptional programs. Their “synthesis” is often distributed across different organs: for vitamin D, intake or cutaneous production constitutes the beginning of a pathway requiring hepatic and renal hydroxylations until the active form is generated. This introduces the concept of the hormone as the product of a multi-organ network, in which the liver and kidney are essential endocrine components, and in which regulation integrates calcium, phosphate, PTH and phosphaturic factors. In these cases, plasma transport bound to specific carriers and local conversion within the target tissue are major determinants of biological activity.
Secretion is the moment when biological information becomes accessible to target compartments, and its physiology depends on how the hormone is packaged and on the type of signal that activates it. For peptide hormones and many amines, secretion is typically regulated, meaning that the hormone is accumulated in granules and released in response to specific stimuli. This allows separation between production and release: the cell can synthesize and process the hormone in advance, whereas exocytosis represents the rapid switch that modulates extracellular concentration within seconds or minutes. Conversely, for steroids and some lipophilic mediators, secretion coincides with synthesis and diffusion, making biosynthesis the physiological bottleneck and turning enzymatic equipment and substrate availability into primary determinants of hormone flux.
In regulated secretion, the secretory stimulus is translated into a cascade of events culminating in vesicle-membrane fusion. The central role is often played by intracellular calcium, which increases through entry via voltage-dependent channels or through release from intracellular stores mediated by second messengers. Calcium interacts with molecular sensors and activates protein complexes that promote docking, priming and fusion of granules. Fusion depends on vesicular and membrane coupling proteins, with a highly conserved sequence that enables temporal precision and fine modulation of secretory output. This model explains clinically relevant phenomena such as biphasic insulin secretion, in which a readily releasable pool and a reserve pool respond with different kinetics, and explains why alterations in stimulus-secretion coupling may generate endocrine dysfunction even when intracellular hormone content is preserved.
The stimulus may be neural, humoral or mechanical. A neural input, such as sympathetic input to the adrenal medulla, produces rapid responses coordinated with physiological state, whereas humoral signals, such as glycemia or calcemia, allow direct autoregulation. Endocrine cells are often specialized “sensors”: pancreatic beta cells translate glucose availability into changes in adenosine triphosphate (ATP) and membrane potential that control calcium entry; parathyroid cells express extracellular calcium-sensing receptors that modulate PTH secretion minute by minute; pituitary cells integrate hypothalamic signals released into the portal system with peripheral feedback signals. This set of architectures allows secretion to be not a simple function of synthesis, but a computational process that combines multiple inputs and converts them into a temporally encoded output.
For steroids, secretion is instead a process “without granules” in the classical sense. The trophic stimulus (such as ACTH or angiotensin II) activates signaling pathways that increase cholesterol availability and enzymatic capacity, accelerating the production of hormones that diffuse out of the cell according to concentration gradients. Regulation may be acute, with post-translational modifications and rapid activation of proteins that mobilize substrate, or chronic, with transcriptional remodeling of steroidogenic enzymes. The diffusive nature of steroids implies that the cell cannot easily “retain” the finished product, but can modulate its production: this makes steroidogenesis a paradigmatic example of metabolic flux control as an endocrine mechanism.
A cross-cutting aspect is that endocrine secretion is rarely perfectly continuous. Many axes exhibit pulsatility and rhythmicity, and pulse frequency may carry biological information. This has important consequences: the same mean secretion may have different effects if distributed in pulses rather than as tonic release, because receptors and intracellular pathways have their own timelines of desensitization, downregulation and recovery. In axes such as the gonadotropic axis, pulsatile dynamics are an essential component of function, and correct endocrine analysis requires considering that a single blood sample may capture different phases of the secretory cycle. In addition, clearance and plasma distribution contribute to “filtering” the signal: hormones with short half-lives better preserve temporal information, whereas hormones with long half-lives tend to integrate the signal over slower time scales.
Blood transport is the step that connects secretion to receptor availability in tissues, and it represents a key determinant of bioavailability. Some hormones, especially hydrophilic ones, travel largely free in plasma and rapidly reach membrane receptors, whereas many lipophilic hormones circulate mainly bound to transport proteins. The central physiological concept is that the free, unbound fraction is the one most directly available to cross capillaries and interact with receptors or cellular transport systems, while the bound fraction acts as a dynamic reservoir that stabilizes free concentration and prolongs half-life. This principle, often summarized as the “free hormone hypothesis”, is fundamental for interpreting relationships between total concentration and biological activity and for understanding many clinical situations in which changes in carrier proteins modify laboratory values without reflecting a true endocrine hyperfunction or hypofunction.
The main carrier proteins include albumin (low affinity and high capacity) and specific high-affinity proteins such as thyroxine-binding globulin (TBG) and transthyretin for thyroid hormones, corticosteroid-binding globulin (CBG) for glucocorticoids and sex hormone-binding globulin (SHBG) for sex steroids. The equilibrium between free and bound hormone is governed by binding affinity, carrier concentration and the presence of competitors. Since the free fraction represents a very small fraction for some hormones, small changes in carrier quantity or binding capacity may produce relevant changes in total concentration with minimal changes in the free fraction. From a physiological standpoint, the system behaves as a buffer: when secretion increases, part of the excess is absorbed by the bound compartment; when secretion decreases, the hormone dissociates, keeping the free fraction more stable. This buffering is particularly important for hormones with chronic action and for systems in which wide fluctuations would be harmful.
Bioavailability also depends on microcirculation and capillary permeability. In compartments with fenestrated endothelium, typical of many endocrine glands, hormone entry into the blood is facilitated; in target tissues, access may be modulated by extravascular binding, interstitial proteins and active transport. Furthermore, for some molecular classes, the presence of carrier proteins does not eliminate the possibility of cellular entry of the free hormone, but modulates its renewal rate. The result is that plasma transport is not a simple “vehicle”, but a kinetic regulator capable of transforming a secretory signal into a tissue exposure profile.
Distribution into tissues introduces an additional level: some organs express specific membrane transport systems for lipophilic hormones that do not freely cross the membrane, as in the case of thyroid hormones, which may require dedicated transporters for cellular entry. In these scenarios, the free plasma concentration does not necessarily coincide with the intracellular concentration, because availability depends on transporter expression and functionality and on intracellular conversion into more active metabolites. This concept helps explain how two tissues may experience different hormonal exposures despite identical serum values, and why endocrine physiology cannot be reduced to a single “central” concentration valid for all compartments.
Bound transport also substantially influences half-life. Bound hormones are protected from glomerular filtration and enzymatic degradation, prolonging residence time and favoring more stable signals. Peptide hormones, which circulate largely free, are instead subject to rapid degradation by plasma and tissue peptidases and to renal or hepatic clearance, a feature reflected in faster dynamics and in the need for more continuous or more frequently pulsatile secretion to maintain functional levels. The difference between “fast” and “slow” hormones is therefore often an emergent property of their transport and stability within the vascular compartment.
Many endocrine systems do not directly produce the only biologically relevant form of the hormone, but release circulating precursors that are converted in peripheral tissues. This principle allows control to be distributed: the gland establishes a systemic “tone”, while target tissues locally modulate signal intensity. Thyroid hormones are the best-known example: a significant proportion of production is T4, which functions as a prohormone, whereas the main receptor activity is mediated by T3. Conversion depends on deiodinases with tissue-specific distribution, capable of both activating and inactivating thyroid hormones. As a result, tissue thyroid status may diverge from plasma status, particularly in systemic disease, inflammation or metabolic disturbances that remodel deiodinase expression or activity.
A parallel concept is the conversion between active and inactive forms of steroids through local enzymes. In the case of glucocorticoids, interconversion between cortisol and cortisone in selected tissues modulates receptor exposure and allows some compartments to be protected from excessive glucocorticoid effects while maintaining adequate systemic concentrations. Similarly, in androgen metabolism, local conversions may determine marked differences in biological activity at the cutaneous, genital or prostatic level compared with the circulating compartment. These mechanisms emphasize that endocrinology is also a discipline of peripheral tissue biology, in which conversion enzymes function as “valves” that amplify or attenuate the information coming from the gland.
Peripheral conversion also includes vitamin D activation, which requires sequential hydroxylations until the active form is produced. In this case, endocrine production is distributed along a chain of transformations involving multiple organs and responding to mineral and hormonal signals, making the system highly adaptive to diet, sun exposure, renal function and bone status. The physiological logic is to maintain strict control over activity, because the active form has powerful effects on intestinal absorption of calcium and phosphate and on bone remodeling.
From a quantitative standpoint, peripheral conversion influences apparent clearance and the temporal profile. A hormone prolonged through conversion into a more active form may produce effects extending beyond the half-life of the secreted molecule, whereas local inactivation may reduce efficacy despite normal serum levels. In addition, the presence of metabolites with different receptor affinities complicates interpretation of total concentration: some metabolites may compete for receptors, others may act on different receptors or have partial activity, creating a functional “mixture” that varies across tissues and physiopathological conditions.
The duration of hormonal action depends not only on secretion and transport, but also on the speed with which the hormone is removed from the circulating compartment and inactivated. The concept of clearance integrates multiple processes: enzymatic degradation in plasma and tissues, hepatic uptake, phase I and phase II metabolism with conjugation, biliary and renal excretion, glomerular filtration for unbound molecules and receptor-mediated removal through endocytosis and lysosomal degradation. In physiological terms, clearance determines how much secretion is required to maintain a given free concentration and how faithfully a pulsatile profile is transmitted to target tissues.
Peptide hormones are typically subject to rapid proteolysis by peptidases and to renal removal, with half-lives often measured in minutes. Some have partial protection through binding to proteins or formation of complexes, but the general rule is that their stability is limited and that secretion must be dynamic to ensure continuous exposure. This explains why many peptide endocrine dysfunctions manifest rapidly and why monitoring may require attention to sampling timing and pulsatile variability.
Lipophilic hormones, especially when bound to specific carriers, have longer half-lives. Removal often occurs through hepatic metabolism with oxidative reactions followed by conjugation (glucuronidation or sulfation), which increases solubility and promotes renal or biliary elimination. Enterohepatic circulation may help prolong exposure for some conjugated molecules that are hydrolyzed and reabsorbed. These mechanisms stabilize the signal, but also make the system sensitive to changes in hepatic function, bile composition, the microbiota and renal function.
Clearance is not merely a “passive” process, because it can be regulated. Changes in carrier concentration alter the fraction available for filtration and metabolism; variations in hepatic or renal enzyme activity change the speed of inactivation; inflammation and systemic disease may remodel both transport proteins and metabolic enzymes. It follows that the same secretory rate may produce different levels under different conditions, and that part of endocrine pathophysiology consists of altered removal rather than altered production. Understanding this point is essential for correctly interpreting states such as acute systemic disease, pregnancy or conditions that modify transport proteins, where total levels may change significantly without reflecting proportional changes in the free fraction.
The physiology of synthesis, secretion, transport and clearance has direct consequences for how hormones are measured and interpreted. A central point is the distinction between concentration and flux: plasma concentration is the instantaneous result of the equilibrium between secretion and removal, whereas secretory flux represents actual production. In systems with strong pulsatility and rapid clearance, concentration may vary widely within minutes, and a single sample may not represent the mean state of the axis. In systems with strong carrier binding and slow clearance, total concentration is more stable but may be influenced by variability in transport proteins, requiring attention to the free fraction or to indices that estimate it reliably.
Immunoassays made modern clinical endocrinology possible, but they have critical limitations related to cross-reactivity, interferences and differences between methods. For steroid hormones and for analytes in which specificity is crucial, methods based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) have gained an increasing role because they improve selectivity and comparability. Method selection is an applied physiological element: accurate assessment of hormonal exposure requires that the measurement correspond to the biologically relevant form and that it take into account the context of transport and conversion. For thyroid hormones, measurement of the free fraction is conceptually consistent with bioavailability, but technically complex and influenced by conditions that alter binding and distribution; for sex steroids, total concentration often needs to be interpreted together with SHBG and with estimates or measurements of the free fraction, especially in conditions that modify the carrier.
Dynamic tests in endocrinology are a direct extension of secretion physiology. When secretion is regulated and depends on well-defined stimuli, the response to a stimulation or suppression test reflects the system’s capacity to generate an appropriate signal and comply with feedback mechanisms. Such tests are particularly informative for axes with secretory reserves and for conditions in which a basal value may be misleading because of pulsatility or circadian variation. Correct interpretation, however, requires knowledge of the kinetics of the hormone and its carrier: sampling times and diagnostic thresholds depend on half-life, release rate and transport setting. In this sense, physiology is not a theoretical chapter, but the necessary basis for understanding why a given diagnostic protocol works and which preanalytical or interpretive errors may compromise its reliability.
Finally, hormone kinetics help explain how complex physiological states modulate endocrinology without necessarily implying a “disease” of the gland. Pregnancy, weight changes, acute and chronic stress, inflammation and organ dysfunction alter transport proteins, peripheral conversions and clearance, remodeling the endocrine setting in an adaptive or maladaptive manner. Clinical endocrinology therefore requires the ability to recognize when a laboratory change represents a true defect in synthesis, when it is a transport effect and when it derives from modified removal or tissue conversion. Understanding the synthesis-secretion-transport-clearance sequence constitutes the essential alphabet for correctly interpreting every endocrine axis.